4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors

US8916574B2 · kind B2 · utility

Assignee

• QILU PHARMACEUTICAL CO., LTD. · CN

Inventors

• Jingyi Wang · Chengdu, CN
• Chuanwen Fan · Shandong, CN
• Long Zhang · Hunan, CN
• Zhongru Guo · Beijing, CN
• Ying Li · Millburn, US
• Shaobo Yang · Dongguan, CN
• Shousheng Yan · Shandong, CN
• Jianrong Zhu · Hunan, CN
• Qingmin Yang · Ann Arbor, US
• Minghui Zhang · Beijing, CN

Key dates

• Filing date: Sep 20, 2010
• Grant date: Dec 23, 2014
• Expiry date: Jan 18, 2031

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to 4-(substituted anilino)-quinazoline derivatives as tyrosine kinase inhibitors. Specifically, compounds of formula I, or pharmaceutically acceptable salts or solvates thereof are disclosed, in which each substitutent in formula I is defined in the description. Preparation method of the compounds of formula I, pharmaceutical compositions and pharmaceutical uses thereof are also disclosed. The compounds of formula I are effective tyrosine kinase inhibitors.